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Abstract
Background In a subpopulation of patients with essential
hypertension, therapeutic targets are not met, despite the
use of multiple types of medication. In this paper we
describe our first experience with a novel percutaneous
treatment modality using renal artery radiofrequency (RF)
ablation.
Methods Patients who were resistant to at least three types of
antihypertensive medical therapy (office systolic blood
pressure≥160 mmHg; n=9) or who did not tolerate
medication (n=2) were selected. Between July and Novem-
ber 2010, a total of 11 patients received percutaneous RF
treatment. Patients were followed up for 1 month after
treatment. Urine and blood samples were taken to evaluate
the effects on renal function and neurohumeral factors.
Results No periprocedural complications or adverse events
during follow-up were noted. A reduction of mean office
blood pressure was seen from 203/109±32/19 mmHg at
baseline to 178/97±28/21 mmHg at 1 month follow-up
(mean difference 25±12 mmHg, p<0.01). Also, we noted a
significant decrease in aldosterone level (391±210 pmol/L
versus 250±142 pmol/L; p=0.03), while there was no
decrease in plasma renin activity (190±134 fmol/L/s versus
195±163 fmol/L/s; p=0.43). No change in renal function
was noted.
Conclusion Catheter-based renal denervation seems an
attractive novel minimally invasive treatment option in
patients with resistant hypertension, with a low risk of
serious adverse events.
Keywords Hypertension.Percutaneous.Radiofrequency
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Background
Using the World Health Organisation criteria of 2001
(systolic blood pressure ≥140 mmHg and/or a diastolic
blood pressure ≥90 mmHg), 34% of adult men and 30% of
women in the Netherlands suffer from hypertension [1].
This prevalence increases strongly with age in both men
and women.
Treatment of hypertension remains suboptimal. Despite
the availability of numerous safe and effective pharmaco-
logical therapies, the percentage of patients achieving
adequate blood pressure control to guideline target values
remains inadequate. The Julius Centre for Health Sciences
and Primary Care in Utrecht recently reported that among
patients with hypertension, only 33.7% were aware of the
condition. Of those aware patients, only 59.4% were
treated. Of those patients treated, 41.9% had blood pressure
at or below the advised level [2]. Frequent failure of the
pharmacological strategy to attain adequate blood pressure
control can be attributed to both physicians’ negligence as
well as patient non-compliance to a lifelong pharmacolog-
ical therapy for a mainly asymptomatic disease. Thus, the
development of new approaches for the management of
hypertension, especially those that could help overcome
these issues, is a priority. These considerations are
especially relevant to patients with drug-resistant hyperten-
sion and/or patients with severe intolerance to medication.
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not exactly known, but cross-sectional studies suggest that
it affects approximately 10–15% of patients being treated
for hypertension by primary care physicians [3].
Renal sympathetic efferent and afferent nerves, which lie
within and immediately adjacent to the wall of the renal
artery, are crucial for initiation and maintenance of systemic
hypertension. Radical surgical methods for sympathetic
denervation have been successful in lowering blood
pressure in severely hypertensive patients. However, these
methods were associated with high perioperative morbidity
and even mortality and also long-term complications [4].
Recently, a percutaneous, catheter-based approach using
radiofrequency energy (RF) was developed to disrupt renal
sympathetic nerves. This resulted in no severe (long-term)
vascular or renal injury. Importantly, catheter-based renal
nerve ablation was associated with a significant reduction
in both systolic and diastolic blood pressure on top of
maximal medical therapy, which persisted throughout
12 months follow-up in the first-in-man study [5]. The
Symplicity HTN-2 Trial was recently published, which was
the first randomised controlled study using this technique of
renal denervation, confirming the findings of the first-in-
man study [6].
Here, we report the results of the first Dutch experience
regarding this novel treatment modality.
Methods
Patient group
Patients were eligible if they have an office systolic blood
pressure of 160 mmHg or more, despite being treated with
at least three antihypertensive drugs, or confirmed intoler-
ance to medication. Blood pressure measurements were
performed in a seated position in at least two subsequent
visits in both arms. Blood pressure check was performed
before intervention and at 1 month follow-up.
Also, renal function and changes in neurohumeral
factors were obtained during follow-up.
The renal artery anatomy was considered suitable in case
of a vessel diameter of ≥4 mm, no prior renal angioplasty/
stenting and no significant stenosis or other abnormalities.
Exclusion criteria for this treatment modality were
pregnancy, age below 18 years, patients with any known
secondary cause of hypertension and a glomerular filtration
rate estimated at <45 mL/min/1.73 m². Also, patients with
type 1 diabetes, haemodynamically significant valvular
disease, implantable cardioverter defibrillators, or who are
on treatment with clonidine, moxonidine, rilmenidine, or
warfarin, were excluded from intervention.
Procedure
Patients were pretreated with diazepam 5 mg and mid-
azolam 1 mg. Using local anaesthetics, cannulation of the
femoral artery was performed using the standard Seldinger
technique. An 8Fr sheath was introduced and unfractio-
nated heparin was given using an intravenous bolus of
1000 IE/kg bodyweight with a target activated clotting time
(ACT) >250 s. Using an 8Fr renal double curve (RDC) or
left internal mammary artery (LIMA) renal guiding catheter
and a 5Fr soft tip straight delivery catheter, a steerable
catheter with radiofrequency energy electrode tip was
delivered into the renal artery. Before treatment, a starting
dose of fentanyl 50 μg was given. A bilateral treatment of
the renal arteries was performed with the use of series of 2-
minute RF energy deliveries along each artery, aiming at 4–
6 treatment points per artery (approximately 8 Watts of
energy per treatment point). These treatment points are
made with a minimum of 5 mm distance in between and
with a pullback from distal to proximal in a circumferential
way. A control angiography was performed after the
procedure. Also, in a subset of three patients, intravascular
ultrasound (IVUS) was performed.
Statistical analysis
Continuous variables are described with mean±standard
deviation. Dichotomous variables are reported as numbers
(percentages). For comparison within different time points,
a paired t test was used. A two-sided alpha level of 0.05
was used for superiority testing. All statistical analyses
were done with PASW Statistics version 17.0 (IBM SPSS,
Somers, NY, USA).
Results
The baseline characteristics of the patient group are listed in
Table 1. The mean time of the procedure (i.e. from puncture
of the femoral artery to closure) was 74±9 min. Mean
fluoroscopy time was 15±2 min. The ACT time achieved
was 298±74 s. The mean use of contrast was 208±35 ml. A
mean dose of fentanyl of 164±29 μg was given (including
the starting dose of 50 μg). For midazolam the mean
periprocedural dose was 3±1.4 mg (including the starting
dose of 1 mg). In total, an average of 5.1±1 RF ablations
were performed in the left renal artery, and 5.6±1 RF
ablations in the right renal artery.
No patients showed endovascular damage at final
angiography. In a small subgroup IVUS was performed,
which showed no dissections or other intravascular com-
plications (n=3).
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creatinine (78±17 μmol/L before compared with 78±
16 μmol/L; p=0.92). There was a statistically significant,
but clinically not relevant, drop in haemoglobin of 9.0±
0.7 mmol/L to 8.6±0.7 mmol/L; p<0.01). In general, there
were no periprocedural (particularly access site) complica-
tions and/or complications during follow-up. No changes in
medication were noted at 1-month follow-up.
As depicted in Fig. 1, the systolic office blood pressure
decreased from 203±32 mmHg at baseline to 178±
28 mmHg at 1 month follow-up. This is a decrease of 25
±12mmHg(p<0.01). The diastolic blood pressure changed
from 109±19 mmHg at baseline to 97±21 mmHg at
follow-up (decrease of 12±11 mmHg; p<0.01).
The plasma renin activity did not change (190±
134 fmol/L/s versus 195±163 fmol/L/s; p=0.43). Interest-
ingly, there was a decrease in aldosterone level (391±
210 pmol/L versus 250±142 pmol/L; p=0.03). In urine
samples taken before and 1 month after the procedure, no
significant decrease in microalbuminuria (39±80 mg/L
versus 27±55 mg/L; p=0.22) and total amount of protein
in the urine was noted (0.14±0.10 g/L versus 0.13±0.07 g/
L; p=0.35).
Discussion
Our first experience with renal sympathetic denervation,
using a percutaneous approach, confirms the results of the
previous proof-of-principle and recent randomised study,
showing the safety and efficacy of this new treatment
modality in daily clinical practice for patients with therapy-
resistant hypertension [5, 6].
The decrease of blood pressure achieved in our patient
population is comparable with that achieved in the previous
studies and most likely will be clinically relevant, although
current guideline target values were not met in our patients
with extreme hypertension (baseline blood pressure 200/
106 mmHg)[7]. A recent meta-analysis by Law et al.
showed that irrespective of the type of medication used, the
incidence of coronary heart disease events was reduced by
22% after a systolic blood pressure reduction of 10 mmHg
or a diastolic blood pressure reduction of 5 mmHg. Even
more, the incidence of stroke was reduced by 41% [8].
Assuming that the effects of renal denervation are as
effective in reducing clinical events as a pharmacological
approach for the treatment of hypertension, the observed
blood pressure reduction of 25/12 mmHg in our patients
will most likely be highly beneficial.
The efficacy of this new treatment option should not only
be present in the short term, but particularly during long-term
follow-up.Severalpatientstreatedwiththisnewtechnique are
nowapproachingthe 2-yearfollow-up,andthe bloodpressure
reductions observed appear to be sustained over this period,
Fig. 1 Mean systolic and diastolic blood pressure before and after
renal denervation (RDN)
Table 1 Baseline characteristics of the patients (n=11)
Age (years) 68±12
Sex (female) 10 (91)
Race (Caucasian) 11 (100%)
Weight (kg) 82±20
Length (cm) 165±11
Body mass index 30±8
Medical history
- CAD 5 (45%)
- CVA/TIA 2 (18%)
- Diabetes 2 (18%)
- Hypercholesterolaemia 4 (36%)
Baseline SBP (mmHg) 203±32
Baseline DBP (mmHg) 109±19
Number of antihypertensive medications 3.1±1.5
Patients on medication
- Beta blockers 8 (73%)
- ACE inhibitors/ARBs 9 (82%)
- Calcium channel blockers 3 (27%
- Vasodilators 2 (18%)
- Diuretics 5 (45%)
- Renin blocker 2 (18%)
- Alpha blockers 2 (18%)
Serum creatinine (μmol/L) 78±17
eGFR (ml/min/1.73m
2)7 4 ± 1 4
ACE angiotensin-converting enzyme, ARB angiotensin receptor
blocker, CVA cerebrovascular accident, DBP diastolic blood pressure,
GFR glomerular filtration rate, SBP systolic blood pressure, TIA
transient ischaemic attack
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regrowth, or development of counter-regulatory blood pres-
sure–elevating mechanisms [9].
Besides efficacy, safety remains an equally important
issue in a therapy for (secondary) prevention of disease. No
adverse events were noted in our first patients periproce-
durally and/or at follow-up. In the first cohort study
performed in a multicentre setting, no renal artery stenosis
occurred as verified using follow-up renal magnetic
resonance angiogram at 6 months [5]. Among all patients
treated worldwide, a local dissection without sequelae was
noted during the procedure in 2 patients, a few access site
bleedings were reported, but no (long-term) side effects
have been published up till now [6]. Particularly, no change
in renal function has been noted.
There is accumulating preclinical and clinical evidence
compelling for a primary role of renal sympathetic
activation in the pathogenesis of hypertension as described
in recent review articles [10, 11]. A crosstalk between the
central nervous system and the kidneys is present (Fig. 2).
Blocking sympathetic nerves leading to the kidney (‘effer-
ent’) will reverse fluid and salt retention. By blocking
sympathetic nerves emanating from the kidney (‘afferent’),
renal denervation may also decrease the stimulation of other
parts of the sympathetic nervous system, such as the heart
and blood vessels, leading to an additional antihypertensive
effect.
The earliest insight into the influence of intervention of
the sympathetic nerve activity on renal function in
hypertension is that of Claude Bernard in 1859 [12]. He
observed that by cutting the greater splanchnic nerve, he
caused an increased diuresis, whereas electrical renal
sympathetic nerve stimulation produced a reduced diuresis.
However, the surgical approach of (non-specific) renal
denervation coincided with severe side effects as observed
in studies from the 1930 s using surgical denervation of the
sympathetic system of the thoracico-lumbar region and has
therefore been abandoned [13, 14]. Using the catheter-
based renal denervation in patients as described in this
paper, we may have overcome these side effects of non-
specific denervation of the lumbar region [15].
Pathophysiological proof of concept of the denervation
of the renal artery has also been shown in a small subset of
patients [16, 17]. Schlaich et al. demonstrated that the so-
called norepinephrine spillover resulted in a decrease of
40–50%, which was accompanied by halving of renin
activity and an increase in renal plasma flow. In our
population, only a decrease in aldosterone was shown.
Most likely, because of the small size of the population, no
uniform effects of the intervention could be shown on the
neurohumeral level in our population. Moreover, it was
shown that microneurography at baseline and at follow-up
showed a reduction in muscle sympathetic-nerve activity to
normal levels [17].
For future therapeutic application of sympathetic denerva-
tion of the renal arteries, further research is needed to identify
groupsofpatientswhomightbenefitfromthisintervention.In
this light, searching for efficacy in patients with, for instance,
chronic kidney disease, patients with heart failure, diabetes
and obesity will be interesting. Also, studies in milder forms
of essential hypertension should be the next goal of research
using this percutaneous technique. Hereby, hard endpoint
studies are warranted to prove the value of this new
percutaneous technique in daily clinical practice.
Fig. 2 Schematic representation
of the involvement of sympa-
thetic hyperactivity in the path-
ogenesis of hypertension.
Increased plasma levels of
angiotensin II and/or increased
afferent renal nerve activity
stimulates the central nervous
system to increase central sym-
pathetic outflow
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